No alterations in α-synuclein gene dosage observed in sporadic Parkinson's disease
✍ Scribed by Caroline H. Williams-Gray; An Goris; Thomas Foltynie; Joanne Brown; Melanie Maranian; Amie Walton; D. Alastair Compston; Stephen J. Sawcer; Roger A. Barker
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 49 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The presynaptic protein alpha-synuclein is considered to play an important role in the pathophysiology of Parkinson's disease (PD). Point mutations in the alpha-synuclein gene have been demonstrated in familial PD and alpha-synuclein is a major component of Lewy bodies, the pathological hallmark of
## Abstract The expression of α‐synuclein gene can be influenced by the genomic load and/or epigenetic factors. By using quantitative real‐time polymerase chain reaction techniques, we demonstrated that the α‐synuclein gene mRNA expression in sporadic PD did not differ from healthy controls (median
## Abstract α‐Synuclein is one of the main components of Lewy bodies, a pathological marker of Parkinson's disease (PD). Certain missense mutations of the α‐synuclein gene cause familial PD, but the role of the gene in sporadic PD is still controversial. We scrutinized polymorphisms of the α‐synucl
The letter by Papapetropoulos and colleagues presents an additional study correlating ␣-synuclein expression levels and sporadic PD. Previously we and others published studies of mRNA levels of SNCA in PD brains that have been performed using different methods. Some are in agreement with our results
Recent interest has focused on the largest pedigree reported to date with histologically proven Lewy body parkinsonism with an autosomal-dominant mode of transmission.' It consisted of descendants of several immigrants to the United States linked to collateral Italian descendants by a common ancesto